Bausch Health Companies Inc. said it plans to vigorously defend its intellectual property after a U.S. judge ruled some patents for one of its drugs were invalid.
“We are disappointed with today's development. We strongly disagree with any conclusion that our patents are not valid and intend to file an appeal to any such order," Bausch’s Chief Executive Officer Thomas J. Appio said in a press release on Thursday.It’s been a dramatic fall from grace for Bausch, which in its former incarnation as Valeant Pharmaceuticals International Inc. briefly eclipsed Royal Bank of Canada as the nation’s largest publicly-traded company.
Another former Valeant executive and the former head of Philidor were sentenced to a year in prison in 2018 after being convicted of fraud.